CONMED Corp Announces Strategic Exit from Gastroenterology Product Lines
I'm PortAI, I can summarize articles.
CONMED Corp announced its strategic exit from gastroenterology product lines to optimize its portfolio. The company will cease distribution of Gore® VIABIL® stent by January 1, 2026, focusing on core markets like minimally invasive surgery. The exit is expected to dilute EPS by $0.45–$0.55 in 2026 but improve gross margin by 80 basis points. 2025 revenue and EPS guidance remain unchanged.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments